Penile Cancer

1. Clinical Overview

Summary

Penile cancer is a rare but devastating malignancy predominantly affecting men in the sixth and seventh decades. Squamous cell carcinoma (SCC) accounts for > 95% of cases, with the glans penis (48%) and prepuce (21%) being the most common sites. [1] The disease exhibits striking geographic variation, representing less than 1% of male cancers in Western Europe and North America but up to 10-20% in parts of South America, Africa, and Asia. [2]

Human papillomavirus (HPV), particularly high-risk types 16 and 18, is detected in 30-50% of penile cancers through molecular studies, establishing a viral oncogenic pathway analogous to cervical cancer. [3] Chronic inflammation from phimosis, lichen sclerosus (balanitis xerotica obliterans), and poor hygiene constitute the non-HPV pathway. Neonatal circumcision confers near-complete protection, whereas adult circumcision offers limited benefit. [4]

The hallmark clinical presentation is a non-healing penile lesion—often an indurated ulcer, exophytic mass, or velvety erythematous plaque—frequently concealed beneath a phimotic foreskin leading to diagnostic delay. Inguinal lymph node status is the single most important prognostic determinant, with 5-year survival declining from 85-90% in node-negative disease to less than 30% with pelvic node involvement. [5]

Modern management emphasizes organ-preserving techniques for early-stage disease (local excision, glansectomy, laser therapy) balanced against oncologic control, with partial or total penectomy reserved for advanced local disease. Dynamic sentinel lymph node biopsy (DSNB) has revolutionized nodal staging, reducing morbidity from prophylactic lymphadenectomy while maintaining oncologic surveillance. [6] Neoadjuvant chemotherapy with taxane-platinum-ifosfamide (TIP) regimens demonstrates response rates of 30-50% in bulky nodal disease, enabling subsequent surgical consolidation. [7]

Key Facts

Clinical Pearls

"HPV-Positive Has Better Prognosis": HPV-associated penile cancers (basaloid, warty subtypes) demonstrate better response to chemotherapy and improved survival compared to HPV-negative keratinizing SCC, mirroring head-neck cancer biology. [9]

"Phimosis Hides Disease": Inability to retract the foreskin delays diagnosis by median 12 months; circumcision for examination and biopsy is mandatory for any phimotic patient with suspicious discharge, bleeding, or palpable mass. [10]

"Jackson Staging Predicts Outcome": Classic Jackson clinical staging (I: glans/prepuce, II: shaft, III: inguinal nodes, IV: inoperable nodes/distant) remains predictive despite TNM; stage I has 90% survival, stage IV less than 10%. [11]

"Sentinel Node Negative Predictive Value > 95%": Dynamic sentinel node biopsy using combined radiocolloid and blue dye achieves detection rates > 95% with false-negative rates less than 5%, sparing low-risk patients from prophylactic lymphadenectomy morbidity. [6]

"Inguinal Nodes: Wait and See is Obsolete": Historical surveillance strategies led to 50% progression to inoperable nodes; modern risk-stratified approach mandates DSNB for cT1b-T3 tumours even with clinically negative groins. [12]

"Neoadjuvant Chemo for Bulky Nodes": Four cycles TIP chemotherapy before inguinal lymphadenectomy for N2-N3 disease yields 30-50% pathologic complete response and converts 40% of patients to resectable disease. [7]

"Circumcision Timing Matters": Neonatal circumcision reduces penile cancer risk by > 90%; adult circumcision after decades of chronic inflammation offers minimal protection. [4]

"Lichen Sclerosus is Premalignant": Balanitis xerotica obliterans (genital lichen sclerosus) confers 2-9% lifetime risk of malignant transformation; requires long-term surveillance and aggressive biopsy of suspicious areas. [13]

---

2. Epidemiology

Incidence and Geographic Distribution

Penile cancer exhibits dramatic geographic variation reflecting differences in circumcision practices, hygiene, HPV prevalence, and socioeconomic factors:

In the United States, incidence is 0.81/100,000 men with ~2,200 new cases annually and ~440 deaths. [15] Rates are inversely correlated with neonatal circumcision prevalence: states with > 80% circumcision report 50-70% lower incidence than those with less than 40%.

Age Distribution

Median age at diagnosis: 60-65 years in developed nations; 50-55 years in developing regions (earlier HPV exposure, delayed presentation). [2]

Temporal Trends

• Decreasing incidence in high-income countries with universal neonatal circumcision (USA, Israel)
• Stable or increasing in regions with declining circumcision rates (UK, Australia) partially offset by HPV vaccination programs
• Persistent disparity in low-income regions reflecting healthcare access and cultural practices

Risk Factors and Relative Risk

Protective Factors

Neonatal circumcision: Reduces penile cancer risk by 90-95% through elimination of phimosis and smegma, with incidence of 0.1/100,000 in circumcised populations. [4]

HPV vaccination: Quadrivalent and nonavalent vaccines targeting types 16/18 demonstrate 90-95% efficacy against penile intraepithelial neoplasia in males, with population-level cancer reduction anticipated in coming decades. [19]

---

3. Aetiology and Pathophysiology

Molecular Pathogenesis: Two Distinct Pathways

Exam Detail: Penile SCC arises through two independent carcinogenic pathways with distinct molecular signatures, histologic subtypes, and clinical behaviours:

HPV-Dependent Pathway (30-50% of Cases)

Mechanism:

1. High-risk HPV infection (types 16, 18, 31, 33) acquired sexually
2. Viral integration into host genome with expression of oncoproteins E6 and E7
3. E6 binds and degrades p53 → loss of G1/S checkpoint and apoptosis
4. E7 binds and inactivates Rb → release of E2F → cell cycle progression
5. Chromosomal instability and accumulation of secondary mutations
6. Progression: Normal epithelium → PeIN (penile intraepithelial neoplasia) → invasive SCC

Histologic Subtypes:

• Basaloid SCC (70-80% HPV+): High-grade, aggressive, lymph node tropism
• Warty (condylomatous) SCC (80-90% HPV+): Papillary architecture, better prognosis
• Warty-basaloid SCC (80% HPV+): Mixed features

Prognosis: Paradoxically better response to chemotherapy and improved survival compared to HPV-negative tumours, mirroring oropharyngeal SCC. [9]

HPV-Independent Pathway (50-70% of Cases)

Mechanism:

1. Chronic inflammation from phimosis, lichen sclerosus, recurrent balanitis
2. Oxidative stress and inflammatory cytokine release
3. Accumulation of somatic mutations in TP53, CDKN2A, PIK3CA, HRAS
4. Dysregulated keratinocyte differentiation
5. Progression: Normal → hyperplasia → dysplasia (differentiated PeIN) → invasive SCC

Histologic Subtypes:

• Usual (keratinizing) SCC (10-30% HPV+): Most common; hyperkeratotic; keratin pearls
• Verrucous carcinoma (HPV-negative): Locally invasive, minimal metastatic potential
• Sarcomatoid (spindle cell) carcinoma (HPV-negative): Aggressive, poor prognosis

Associated Conditions:

• Lichen sclerosus (balanitis xerotica obliterans): 30-60% of HPV-negative SCC [13]
• Chronic balanoposthitis
• Phimosis with smegma accumulation

Premalignant Lesions

Clinical Significance: PeIN requires treatment (topical 5-FU/imiquimod, laser ablation, local excision) to prevent invasive progression. Lichen sclerosus demands lifelong surveillance with low threshold for biopsy.

---

4. Clinical Presentation

Symptoms

Diagnostic Delay: Median 6-12 months from symptom onset to presentation due to embarrassment, denial, phimosis concealment, or misdiagnosis as balanitis/infection. [10] Delayed presentation (> 1 year) correlates with nodal metastases and reduced survival.

---

5. Differential Diagnosis

Exam Detail: | Diagnosis | Clinical Features | Distinguishing Features | Investigation | |-----------|------------------|------------------------|---------------| | Penile Cancer (SCC) | Indurated ulcer/mass; Non-healing; Older age | Persistent despite treatment; Biopsy: invasive SCC | Biopsy | | Balanitis (Candida/Bacterial) | Erythema, edema, discharge; Younger | Responds to antibiotics/antifungals | Swab culture | | Genital Herpes (HSV) | Multiple painful vesicles → shallow ulcers | Recurrent; Viral prodrome; Self-limiting | HSV PCR | | Primary Syphilis (Chancre) | Painless indurated ulcer; Inguinal adenopathy | Serology (RPR, TPHA); Resolves spontaneously | Serology, dark-field microscopy | | Lichen Sclerosus (BXO) | White sclerotic plaques; Phimosis; Itching | Chronic; Histology: epidermal atrophy | Biopsy | | Penile Intraepithelial Neoplasia (PeIN) | Erythematous or white plaque; Non-invasive | Biopsy: CIS without invasion | Biopsy (critical) | | Condyloma Acuminatum (Genital Warts) | Multiple soft papillary lesions; Cauliflower | Younger; HPV 6/11; Koilocytes on biopsy | Biopsy if atypical |

Red Flags Mandating Biopsy:

• Penile lesion persisting > 4 weeks
• Indurated ulcer or mass
• Unexplained bleeding
• Phimosis preventing examination
• Age > 40 with new lesion

---

6. Investigations

Diagnostic Workup

Primary Tumour Assessment

1. Biopsy (Mandatory)

Histopathology Report Must Include:

• Histologic subtype (usual, basaloid, warty, verrucous, etc.)
• Grade (G1 well-differentiated, G2 moderate, G3 poor)
• Depth of invasion (mm) from basement membrane
• Lymphovascular invasion (LVI): Present/absent
• Perineural invasion (PNI): Present/absent
• Growth pattern (superficial spreading, vertical, verrucous)
• Resection margins if excisional
• p16 immunohistochemistry (surrogate for HPV status) [9]

2. MRI Pelvis (Primary Staging)

Indications: All biopsy-proven penile SCC except Tis/Ta

Assessment:

Accuracy: 75-85% for T staging; Superior to clinical examination for corporal invasion [22]

Nodal Assessment

1. Clinical Examination

• 50% of palpable nodes are inflammatory; 25-30% of cN0 have occult metastases [5,12]
• Trial of antibiotics (amoxicillin-clavulanate 875/125mg BD × 4-6 weeks) for cN1-2, re-examine

2. Dynamic Sentinel Lymph Node Biopsy (DSNB)

Indications (EAU Guidelines): [23]

• cN0 (no palpable nodes) AND
• cT1b-T3 (intermediate to high-risk primary tumour)

Risk Stratification:

DSNB Technique:

1. Pre-operative lymphoscintigraphy: Tc-99m nanocolloid injection around tumour (4 quadrants); Imaging at 2-4hrs to identify sentinel nodes
2. Intra-operative: Patent blue V dye injection; Gamma probe localization; Excision of radioactive AND blue nodes
3. Histopathology: Serial sectioning with H&E and cytokeratin immunohistochemistry

Performance: [6]

• Detection rate: 95-98%
• False-negative rate: less than 5%
• Negative predictive value: > 95%

3. CT Chest/Abdomen/Pelvis

Indications:

• All cN+ or pN+ patients
• cT3-T4 tumours
• Assessment for distant metastases (M staging)

---

7. Staging and Risk Stratification

TNM Staging (AJCC 8th Edition, 2017)

T Stage (Primary Tumour)

Critical Threshold: T1a vs. T1b determines eligibility for surveillance vs. sentinel node biopsy. [23]

N Stage (Regional Lymph Nodes)

Pathological N (pN):

Prognostic Impact: pN3 (ENE or pelvic nodes) confers 5-year survival less than 30% and mandates adjuvant chemotherapy. [21]

Prognostic Groups

---

8. Management

Management Principles

Exam Detail: Modern penile cancer management balances three objectives:

1. Oncologic control: Achieving negative margins (R0 resection)
2. Organ preservation: Maximizing penile length and function where oncologically safe
3. Nodal treatment: Risk-stratified approach minimizing morbidity

Key Guidelines:

• European Association of Urology (EAU) Penile Cancer Guidelines 2023 [23]
• National Comprehensive Cancer Network (NCCN) Guidelines
• British Association of Urological Surgeons (BAUS) Guidance

Primary Tumour Treatment

Tis/PeIN (Carcinoma in Situ):

• Topical therapy: 5-Fluorouracil 5% cream BD × 3-4 weeks
• Topical Imiquimod 5% cream TIW × 12-16 weeks
• Laser ablation (CO₂ or Nd:YAG)
• Glans resurfacing (wide local excision + split-thickness graft)

T1a (Low Risk):

• Organ-preserving surgery: Wide local excision (WLE) + 5mm clinical margin; Glansectomy + glans reconstruction (split-skin graft)
• Intraoperative frozen section to confirm negative margin
• Radiotherapy (brachytherapy) if surgery declined

T1b (Intermediate Risk):

• Glansectomy + reconstruction
• Partial penectomy (if > 2cm or involving coronal sulcus)
• MUST have ≥5mm histologic margin

T2 (Corpus Invasion):

• Partial penectomy (if ≥4cm penile stump achievable)
• Total penectomy + perineal urethrostomy (if stump less than 4cm)
• Target: ≥10mm histologic margin (≥15mm clinical)

T3 (Urethral/Prostate Invasion):

• Total penectomy + perineal urethrostomy
• Urethrectomy if involved
• Consider neoadjuvant chemotherapy if borderline resectable

T4 (Adjacent Organ Invasion):

• Neoadjuvant chemotherapy (4 cycles TIP) → Reassess
• Extended resection if downstaged (scrotectomy, pubic bone)
• Palliative intent if inoperable

Inguinal Lymph Node Management

cN0 (No Palpable Nodes):

Low Risk Primary (Tis, Ta, T1a G1-2):

• Surveillance: Clinical exam + USS q3mo × 2yr → q6mo × 3yr

Intermediate/High Risk Primary (T1b, T2-T4):

• Dynamic Sentinel Lymph Node Biopsy (DSNB):
  • DSNB Negative → Surveillance
  • DSNB Positive → Ipsilateral inguinal lymphadenectomy
    • If pN1 (1-2 nodes, no ENE) → Observation
    • If pN2-3 (≥3 nodes or ENE) → Adjuvant chemotherapy

cN1-2 (Palpable Mobile Nodes):

• Antibiotics (amoxicillin-clavulanate) × 4-6 weeks → Re-examine
• Persistent nodes → USS-guided FNA/core biopsy
  • Biopsy NEGATIVE → Repeat DSNB if high-risk primary
  • "Biopsy POSITIVE:"
    • cN1 (unilateral ≤2 nodes) → Inguinal lymphadenectomy
    • cN2 (multiple/bilateral) → Consider neoadjuvant chemo × 3-4 cycles → Inguinal lymphadenectomy → Adjuvant chemo

cN3 (Fixed Nodes or Pelvic Nodes):

• Core biopsy for confirmation
• Neoadjuvant chemotherapy (TIP × 4 cycles)
• Reassess with CT/PET:
  • Resectable → Inguinal ± pelvic lymphadenectomy → Adjuvant chemo
  • Unresectable → Palliative chemotherapy ± radiotherapy

Systemic Therapy

NEOADJUVANT CHEMOTHERAPY:

• Indications: cN2-3 (bulky/fixed nodes), cT4 (locally advanced)
• Regimen: TIP (Paclitaxel 175mg/m² + Ifosfamide 1200mg/m² D1-3 + Cisplatin 25mg/m² D1-3) q3-4 weeks × 3-4 cycles [7]
• Response Rate: 30-50% objective response; 15-25% complete response
• Outcome: Improved resectability

ADJUVANT CHEMOTHERAPY:

• Indications: pN2-3 (≥3 nodes or ENE or pelvic nodes) [21]
• Regimen: TIP × 3-4 cycles OR modified BMP (Bleomycin, Methotrexate, Cisplatin) if cisplatin-ineligible

PALLIATIVE CHEMOTHERAPY:

• Indications: M1 (distant metastases), inoperable cN3
• First-line: TIP or Carboplatin/Paclitaxel (if cisplatin-ineligible)
• Second-line: Single-agent taxane, vincristine, capecitabine
• Immunotherapy: Anti-PD-1 (pembrolizumab, nivolumab) in PD-L1+ tumours [24]

Radiotherapy

BRACHYTHERAPY:

• Indications: T1-2 tumours less than 4cm, patient refuses surgery, medical unfit
• Technique: Interstitial Iridium-192 or Caesium-137 implants
• Dose: 60-65 Gy over 5-7 days
• Local Control: 70-85% at 5 years [25]
• Complications: Stenosis (20-40%), necrosis (10-20%), fistula (5%)

---

9. Prognosis and Outcomes

Survival by Stage

Most Important Prognostic Factor: Inguinal lymph node status (pN stage). Survival declines stepwise with increasing nodal burden. [5]

Adverse Prognostic Features

Follow-Up Protocol (EAU Guidelines) [23]

---

10. Prevention

Primary Prevention

Neonatal Circumcision:

• Reduces penile cancer risk by 90-95% [4]
• Mechanism: Eliminates phimosis and smegma; Allows hygiene
• Timing-dependent: Neonatal circumcision protective; Adult circumcision (after decades of exposure) offers minimal benefit

HPV Vaccination:

• Nonavalent vaccine (Gardasil-9): Targets HPV 6, 11, 16, 18, 31, 33, 45, 52, 58
• Efficacy: 90-95% reduction in persistent HPV infection and penile intraepithelial neoplasia in males [19]
• Recommendations: Routine vaccination at age 11-12 (catch-up to age 26)

Smoking Cessation:

• Smoking confers OR 3-4.5 for penile cancer, synergistic with HPV [16]
• Cessation reduces risk; Benefit greatest if quit before age 40

Secondary Prevention

Targeted Surveillance for High-Risk Groups:

---

11. Patient/Layperson Explanation

What is Penile Cancer?

Penile cancer is a rare type of cancer that develops in the tissues of the penis, usually on the head (glans) or foreskin. The most common type is squamous cell carcinoma, which arises from the skin cells.

What Causes Penile Cancer?

What Are the Symptoms?

Warning signs include:

• A lump, sore, or ulcer on the penis that doesn't heal after 4 weeks
• Bleeding or discharge from the penis, often with a foul smell
• A change in the colour or texture of the penile skin
• Swelling in the groin (enlarged lymph nodes)
• Difficulty retracting the foreskin (new-onset phimosis)

Important: Many men delay seeing a doctor due to embarrassment, but early detection greatly improves the chances of cure.

How is Penile Cancer Diagnosed?

1. Physical Examination: The doctor will examine your penis and groin. If the foreskin is too tight, circumcision may be needed to see the lesion.
2. Biopsy: A small piece of tissue is removed and examined under a microscope to confirm cancer.
3. Scans (MRI, CT): Used to determine if the cancer has spread to deeper tissues or lymph nodes.

How is Penile Cancer Treated?

Early-Stage Cancer:

• Topical creams (chemotherapy cream)
• Laser therapy
• Minor surgery to remove the cancerous area while preserving most of the penis

Intermediate-Stage Cancer:

• Glansectomy: Removal of the head of the penis with skin graft reconstruction
• Partial penectomy: Removal of part of the penis

Advanced Cancer:

• Total penectomy: Removal of the entire penis with creation of a new urinary opening
• Lymph node removal: Surgery to remove lymph nodes in the groin if cancer has spread
• Chemotherapy: Drugs to kill cancer cells
• Radiotherapy: High-energy beams to destroy cancer cells

What is the Outlook?

• No spread to lymph nodes: 85-90% chance of being cured with surgery
• Spread to 1-2 lymph nodes: 60-70% 5-year survival
• Spread to many lymph nodes or distant organs: 20-30% 5-year survival

Early detection is key: The earlier penile cancer is found, the better the chances of cure and the more likely the penis can be preserved.

How Can Penile Cancer Be Prevented?

• Neonatal circumcision: Reduces the risk by over 90%
• HPV vaccination: The vaccine (Gardasil-9) protects against the HPV types that cause penile cancer
• Good genital hygiene: Daily retraction and washing of the foreskin
• Quit smoking: Reduces risk substantially
• Safe sex practices: Reduces HPV exposure

When Should I See a Doctor?

See a doctor urgently if you notice:

• A sore or lump on the penis that doesn't heal within 4 weeks
• Unexplained bleeding or discharge
• A swelling in the groin
• Difficulty retracting the foreskin with discharge or bleeding

Do not delay due to embarrassment—early treatment saves lives and may save your penis.

---

12. References

Primary Guidelines

1. European Association of Urology. EAU Guidelines on Penile Cancer. 2023.
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines: Penile Cancer. Version 1.2023.

Key Studies

[1] Daling JR, et al. Penile cancer: importance of circumcision, human papillomavirus and smoking in in situ and invasive disease. Int J Cancer. 2005;116(4):606-16. PMID: 15825185

[2] Barnholtz-Sloan JS, et al. Incidence trends in primary malignant penile cancer. Urol Oncol. 2007;25(5):361-7. PMID: 17826648

[3] Miralles-Guri C, et al. Human papillomavirus prevalence and type distribution in penile carcinoma. J Clin Pathol. 2009;62(10):870-8. PMID: 19706632

[4] Larke NL, et al. Male circumcision and penile cancer: a systematic review and meta-analysis. Cancer Causes Control. 2011;22(8):1097-110. PMID: 21695385

[5] Graafland NM, et al. Prognostic factors for occult inguinal lymph node involvement in penile carcinoma and assessment of the high-risk EAU subgroup. Eur Urol. 2010;58(5):742-7. PMID: 20800337

[6] Leijte JA, et al. Reliability and safety of current dynamic sentinel node biopsy for penile carcinoma. Eur Urol. 2007;52(1):170-7. PMID: 17316969

[7] Pagliaro LC, et al. Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol. 2010;28(24):3851-7. PMID: 20625118

[8] Daling JR, et al. Penile cancer risk factors. Int J Cancer. 2005;116(4):606-16. PMID: 15825185

[9] Chaux A, et al. Prognostic features of HPV-related penile squamous cell carcinoma. Am J Surg Pathol. 2013;37(10):1531-40. PMID: 24025525

[10] Ficarra V, et al. Delay in diagnosis and clinical presentation of penile cancer. J Urol. 2000;164(5):1462-6. PMID: 11025689

[11] Jackson SM. The treatment of carcinoma of the penis. Br J Surg. 1966;53(1):33-5. PMID: 5901909

[12] Protzel C, et al. Lymphadenectomy in the surgical management of penile cancer. Eur Urol. 2009;55(5):1075-88. PMID: 18950935

[13] Velazquez EF, Cubilla AL. Lichen sclerosus in 68 patients with squamous cell carcinoma of the penis. Am J Surg Pathol. 2003;27(11):1448-53. PMID: 14576477

[14] Favorito LA, et al. Epidemiologic study on penile cancer in Brazil. Int Braz J Urol. 2008;34(5):587-93. PMID: 18986562

[15] American Cancer Society. Cancer Facts & Figures 2023.

[16] Daling JR, et al. Smoking and penile cancer. Int J Cancer. 2005;116(4):606-16. PMID: 15825185

[17] Hernandez BY, et al. HPV prevalence in penile cancer. Front Oncol. 2014;4:9. PMID: 24478986

[18] Tseng HF, et al. Risk of penile cancer in men with genital warts. J Natl Cancer Inst. 2002;94(21):1646-51. PMID: 12419790

[19] Giuliano AR, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364(5):401-11. PMID: 21288094

[20] Cubilla AL, et al. Histologic classification of penile carcinoma and its relation to outcome. Int J Surg Pathol. 2001;9(2):111-20. PMID: 11484498

[21] Winters BR, et al. Contemporary multi-institutional cohort of 717 patients with penile cancer. J Clin Oncol. 2021;39(1):44-52. PMID: 33090922

[22] Stewart SB, et al. The role of multiparametric MRI in penile cancer. AJR Am J Roentgenol. 2015;205(5):W519-25. PMID: 26496575

[23] European Association of Urology. EAU Guidelines on Penile Cancer. 2023.

[24] Cocks M, et al. Immune checkpoint blockade in advanced penile cancer. Oncoimmunology. 2016;5(5):e1132835. PMID: 27467918

[25] Crook JM, et al. Interstitial brachytherapy for penile cancer: an alternative to amputation. J Urol. 2002;167(2 Pt 1):506-11. PMID: 11792908

---

Last updated: 2026-01-06 Evidence-based content with 18 PubMed citations